Fagron, the leading global player in pharmaceutical compounding, is pleased to announce the completion of Purifarma in Brazil, an important milestone in executing our disciplined M&A strategy. The completion of this transaction follows competition clearance by CADE, the Brazilian antitrust authority, last October, and will strengthen Fagron’s scalable, high-quality platform, in line with the Group’s long-term growth objectives.

Purifarma is a large-scale Essentials business with a competitive product portfolio and significant volumes. The company provides opportunities to improve mix, extend into industrial clients and capture operating leverage as volumes grow. The transaction is expected to deliver procurement benefits in Latin America and across the wider Group. The enterprise value of this acquisition is c.R$250 million.

Rafael Padilla, CEO of Fagron, commented:
“Completing Purifarma strengthens our position in Brazil and advances our disciplined buy-and-build strategy. Purifarma adds scale in Essentials with clear levers in mix, procurement and access to industrial clients. We will remain selective and execution-focused as we integrate these businesses and build a larger, more efficient platform.

“Thank you to our teams worldwide for disciplined delivery. We have reinforced our positions in core markets, entered attractive new geographies and added capabilities that deepen our vertical integration, all aligned with our long-term ambition.”